A kind of Roseburia and its application

Abstract

The present invention discloses a Rothia species and an application thereof. The Rothia species is Rothia nasimurium, which is deposited in the General Microbiological Center of the China Microbiological Culture Collection Committee, and the deposit address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, with a deposit number of CGMCC No. 30097 and a deposit time of March 22, 2024. The Rothia species has an antibacterial effect on Streptococcus suis, Mycobacterium tuberculosis, Staphylococcus aureus, Corynebacterium siccae, and Streptococcus nongalactolyticus, and is convenient for subsequent use in related scientific research.

Description

Technical Field

[0001] The invention relates to the technical field of microorganisms, in particular to Roseburia and applications thereof. Background Art

[0002] Rothia nasalis is a common conditional pathogen. It is a symbiotic bacteria in the upper respiratory tract and intestines of pigs, humans and other mammals and poultry. However, in recent years, studies have found that the bacteria also have pathogenicity and are pathogenic to Arctic goose embryos, dog skin, ducks and other animals. Rothia is a Gram-positive bacterium that is facultatively anaerobic, does not form spores, and is non-motile. Currently, the genus contains six species, namely Rothia aeria, Rothia amarae, Rothia dentocariosa, Rothiamucilaginosa, Rothia nasimurium and Rothia terrae.

[0003] In 2020, ducks on a farm in Northeast my country developed sporadic respiratory symptoms such as runny nasal discharge, coughing, and shortness of breath, as well as reduced food intake and depression. In order to determine the cause of the disease and propose targeted prevention and treatment plans, nasal swabs of the diseased ducks were collected aseptically for bacterial isolation and culture. The isolated strain was identified as Roseburia murinosa by culture characteristics, staining microscopy, biochemical tests, and 16S rDNA sequence analysis. The results of animal pathogenicity tests showed that the isolated strain had a certain pathogenicity to ducks, and the pathogen that caused the epidemic was Roseburia murinosa from ducks, which was resistant to multiple drugs.

[0004] In the prior art, the invention patent with patent application number CN202110195901.0 provides Roseburia sp. MGB-2, whose deposit number is CGMCC No.1.31010. It has the ability to produce butyrate, and therefore belongs to butyrate-producing bacteria (Faeciroseburia intestinalis). The Roseburia sp. MGB-2 in this patent can significantly control body weight, improve blood sugar, blood lipids and other metabolic syndrome diseases, and can be used to prepare medicines, health products or foods for the treatment of diabetes, lowering blood lipids, obesity and inflammatory bowel disease. However, there is little research on other functions and applications of Roseburia. Summary of the invention

[0005] In view of the problems mentioned in the background technology, the present invention provides a Roseburia and application thereof.

[0006] The above technical objectives of the present invention are achieved through the following technical solutions:

[0007] The invention discloses a Roseburia, which is Rothianasimurium, deposited in the General Microbiology Center of China Microbiological Culture Collection Committee, with the deposit address being Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, with the deposit number being CGMCC No.30097, and the deposit time being March 22, 2024.

[0008] Roseburia, whose sequence is shown in SEQ ID NO:1.

[0009] The present invention also discloses the use of the above-mentioned Rothia in drugs with antibacterial effect, such as being used for preparing drugs with antibacterial effect.

[0010] The metabolites of the Roseburia of the present application are predicted to be three major categories of products: NRPS, betalactone, and lanthipeptide secondary metabolic gene clusters.

[0011] Preferably, Roseburia is used in a drug having an antibacterial effect.

[0012] It is further preferred that the antibacterial effect includes antibacterial effect on one or more of Streptococcus suis, Mycobacterium tuberculosis, Staphylococcus aureus, Corynebacterium serrata, and Streptococcus non-galactolyticus.

[0013] A bacterial agent comprises the fermentation broth of the above-mentioned Roseburia, which is a solid or liquid bacterial preparation.

[0014] Beneficial Effects

[0015] The present invention discloses for the first time that Rothia nasimurium has antibacterial effects on Streptococcus suis, Mycobacterium tuberculosis, Staphylococcus aureus, Corynebacterium siccae, and Streptococcus non-galactolyticus, which has a relatively broad prospect for subsequent applications and is convenient for subsequent use in related scientific research. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 This is a morphological picture of Rothia nasimurium under a microscope, 100 times oil immersion microscope examination;

[0017] Figure 2 Phylogenetic tree identified for the 16S rRNA of R. murinciana. DETAILED DESCRIPTION

[0018] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only those obtained by the technicians of the present invention without creative work. All other embodiments belong to the scope of protection of the present invention. Unless otherwise specified, the relevant materials appearing in the subsequent embodiments are prepared by the previous embodiments.

[0019] Example 1

[0020] The invention discloses a Rothia species, which is Rothianasimurium, and is deposited in the General Microbiological Center of China Microbiological Culture Collection Administration, with a deposit number of CGMCC No.30097 and a deposit time of March 22, 2024.

[0021] Roseburia, metabolites are divided into three categories: NRPS, betalactone, and lanthipeptide secondary metabolism gene clusters.

[0022] The Rothia bacteria disclosed in the present invention can be used in the preparation of drugs with antibacterial effects, which specifically include antibacterial effects on one or more of Streptococcus suis, Mycobacterium tuberculosis, Staphylococcus aureus, Corynebacterium siccae, and Streptococcus nongalactolyticus.

[0023] The sequence of 16s rRNA of Roseburia murinus is shown in SEQ ID NO: 1. The phylogenetic tree of its 16s rRNA identification is shown in Figure 2 shown.

[0024] Through the antibacterial activity determination experiment, a strain of Roseburia with a broad antibacterial spectrum was screened out, which has antibacterial effects on Streptococcus suis, Mycobacterium tuberculosis, Staphylococcus aureus, Corynebacterium serrata, and Streptococcus lactis.

[0025] Determination of antibacterial activity

[0026] The antibacterial activity of Rothia nasimurium was determined by double-layer agar plate method. Take 5 μL of overnight culture solution of Rothia nasimurium (about 10 7 CFU) was placed in the center of the MHA plate to form an inoculation point with a diameter of 0.5 cm. After inverted culture at 37°C for 24 h, the MHA semi-solid medium cooled to about 55°C after autoclaving was taken and the bacterial suspension of indicator bacteria was added to the concentration of indicator bacteria to about 10 6 CFU / mL (adjust the bacterial solution concentration to 0.5 McFarland turbidity, then add it to MHA semi-solid culture medium and dilute it 100 times), shake it well, slowly cover it on the plate inoculated with the test bacteria, dry it, invert it at 37℃ for 24h, and observe the size of the inhibition zone.

[0027] Table 1 shows the results of the antibacterial experiment on Streptococcus suis, Mycobacterium tuberculosis, Staphylococcus aureus, dry Corynebacterium, and non-galactolytic Streptococcus, indicating that Rothianasimurium has an antibacterial effect on Streptococcus suis, Mycobacterium tuberculosis, Staphylococcus aureus, dry Corynebacterium, and non-galactolytic Streptococcus. The results are the diameter of the inhibition zone in mm.

[0028] Table 1

[0029]

[0030]

[0031] Note: The test bacteria selected are pathogens from clinically ill livestock and poultry; the inhibition zone is completely transparent.

[0032] Table 2 shows the antibacterial test results of Rothia nasimurium on Streptococcus suis. Rothia nasimurium has a general antibacterial effect on Streptococcus suis. The experimental results are statistically 100% antibacterial. The results are the diameter of the inhibition zone, in mm.

[0033] Table 2 The antibacterial results of Rothia nasimurium against 20 strains of Streptococcus suis

[0034]

[0035]

Claims

1. A Roseburia species, characterized in that: Roseburia murinsis Rothia nasimurium, It is deposited in the General Microbiology Center of China Microbiological Culture Collection Administration, the deposit address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, the deposit number is CGMCC No.30097, and the deposit date is March 22, 2024.

2. Use of the Roseburia according to claim 1 in the preparation of a drug with an antibacterial effect, wherein the antibacterial drug has an antibacterial effect on one or more of Streptococcus suis, Mycobacterium tuberculosis, Corynebacterium siccae, and Streptococcus non-galactolyticus.

3. A bacterial agent, characterized in that: The invention comprises the Rochester bacteria according to claim 1 and / or the fermentation broth of the Rochester bacteria according to claim 1, which is a solid or liquid bacterial preparation.

Images